A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants
Conditions: Healthy Participants Interventions: Drug: PF-07293893; Drug: Placebo; Drug: Midazolam Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
Conditions: Healthy Volunteers Interventions: Drug: Ritlecitinib Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
Conditions: COVID-19; Coronavirus Disease 2019; Influenza Interventions: Biological: COVID-19 Vaccine Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Conditions: Vitiligo Interventions: Drug: Ritlecitinib; Drug: Ritlecitinib 100 mg; Drug: Placebo Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients: the Study Protocol
Conditions: Metastatic Breast Cancer Interventions: Device: Decision Support System Sponsors: European Institute of Oncology; Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
Conditions: COVID-19 Interventions: Behavioral: Vaccine Messaging; Behavioral: Vaccine Acceptance Question Sponsors: University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer; Duke University; Baylor College of Medicine; Thomas Jefferson University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks
While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 1, 2023 Category: Pharmaceuticals Source Type: clinical trials
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults
Conditions: Healthy Participants; Healthy Subjects Interventions: Drug: Formulation A; Drug: Formulation B; Drug: Formulation C; Drug: Formulation D Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Conditions: Multiple Myeloma Interventions: Drug: Elranatamab; Drug: Elotuzumab; Drug: Pomalidomide; Drug: Dexamethasone; Drug: Bortezomib; Drug: Carfilzomib Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Conditions: Prostatic Neoplasms Interventions: Drug: Novel hormonal therapy Sponsors: Pfizer; Astellas Pharma Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Conditions: Multiple Myeloma Interventions: Drug: Elranatamab; Drug: Elotuzumab; Drug: Pomalidomide; Drug: Dexamethasone; Drug: Bortezomib; Drug: Carfilzomib Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Conditions: Hematologic Diseases; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation Interventions: Device: NewSpringForMe digital solution Sponsors: Fonds de Dotation HTC Project; Saint-Louis Hospital, Paris, France; Nutricia Nutrition Clinique; Clinicprosport; ELLYE; Association A ïda; Gilead Sciences; Pfizer; Groupe Apicil; Association Laurette Fugain; Fondation du LEEM; Fondation AFNIC; Pierre Fabre Medicament; Novartis Pharmaceuticals; University Hospital, Clermont-Ferrand; LAPSCO, Université Clermont-Auvergne Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
Elranatamab in R/R Multiple Myeloma
Conditions: Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple Myeloma Interventions: Drug: Elranatamab Sponsors: Massachusetts General Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
Conditions: Healthy Participants Interventions: Drug: Etrasimod Immediate Release (IR) Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
Conditions: Biological Availability Interventions: Drug: Zavegepant 100mg non-enteric coated soft gel capsule; Drug: Zavegepant 100mg immediate release tablet; Drug: Zavegepant 2 x 100mg immediate release tablets; Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule Sponsors: Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
